Adjuvant Trastuzumab Deruxtecan (Enhertu) & Nivolumab For Patients Who Are Disease Free After Completion of Trimodality Treatment For HER-2+ Cancers of Esophagus & Gastroesophageal Junction
Brown University
Brown University
Jazz Pharmaceuticals
Taiho Oncology, Inc.
Arcus Biosciences, Inc.
Arcus Biosciences, Inc.
Eastern Cooperative Oncology Group
Merck Sharp & Dohme LLC
Seagen Inc.
University of Colorado, Denver
NeoTX Therapeutics Ltd.
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Memorial Sloan Kettering Cancer Center
City of Hope Medical Center
National Cancer Institute (NCI)
SOLTI Breast Cancer Research Group
Merck Sharp & Dohme LLC
University Hospital Schleswig-Holstein